Prosecution Insights
Last updated: April 19, 2026
Application No. 17/747,535

SYSTEM AND APPARATUS FOR MONITORING AND ASSESING CARDIAC ARRHYTHMIAS

Non-Final OA §112
Filed
May 18, 2022
Examiner
LUKJAN, SEBASTIAN X
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
GE Precision Healthcare LLC
OA Round
3 (Non-Final)
76%
Grant Probability
Favorable
3-4
OA Rounds
3y 2m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
383 granted / 503 resolved
+6.1% vs TC avg
Strong +42% interview lift
Without
With
+41.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
40 currently pending
Career history
543
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
48.1%
+8.1% vs TC avg
§102
15.3%
-24.7% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 503 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/6/2026 has been entered. Response to Amendment This office action is in response to the amendment filed on 2/6/2026. Currently claims 1-20 are pending. Response to Arguments Applicant’s arguments, see pg. 10, filed 2/6/2026, with respect to the previous rejection under 35 USC 101 of claims 1-20 have been fully considered and are persuasive based on applicant’s amendments to the claims. The previous rejection under 35 USC 101 of claims 1-20 has been withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 1 as amended recites the limitation: “classify the pulse segment based on pulse morphology” This amendment appears to be broader than what is supported in applicant’s disclosure. If one looks to the disclosure about how classification occurs, the best support appears to be para 20 of applicant’s specification received on 5/18/2022 which states the following: “According to another aspect of the disclosure, a system for monitoring cardiac arrhythmias may include: an ECG monitor configured to obtain ECG data, the ECG data being obtained by measuring cardiac potentials during cardiac cycles; a blood flow monitor configured to obtain secondary data, the secondary data being obtained by measuring a physiological parameter indicative of blood flow; a memory storing instructions; and one or more processors configured to execute the instructions to: detect a presence of an arrhythmia based on the ECG data; classify a pulse segment of secondary data obtained during the arrhythmia based on pulse morphology; assign a slope to the pulse segment based on the classification; multiply the slope of the pulse segment by a length of the pulse segment to obtain a segment value; calculate a shortage value by adding a previous shortage value and the segment value; compare shortage value to a predefined threshold; and trigger an alarm based on the shortage value exceeding a predefined threshold.” Specifically, that classification is performed using data that occurs during an arrhythmia. However, claim 1 has been amended so that there is no longer an arrhythmia detected and the classification can occur regardless if an arrhythmia occurs or not. Thus, what is claimed appears to be broader in scope than what is actually supported in applicant’s disclosure. Thus, claim 1 appears to fail to comply with the written description requirement. Claims 2-16 are also rejected under 35 USC 112(a) based on dependency to claim 1. Claims 1-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 1-16: As outlined above in claim 1 appears to claim a broader scope that what is actually disclosed (i.e. specifically that classification of a pulse segment based on pulse morphology alone without any indication if this pulse segment is obtained during the arrhythmia). Since the disclosure fails to fully support this broader scope, the metes and boundaries of the embodiments covered by this broader scope are not clear rendering this the limitation “classify the pulse segment based on pulse morphology” in claim 1 indefinite. Thereby, rendering claim 1 indefinite. Additionally, claims 2-16 are rejected under 35 USC 112(b) as well based on dependency to claim 1. Regarding claims 17-20: Claim 17 recites the limitation "the arrhythmia" in the limitation “classify the pulse segment of secondary data obtained during the arrhythmia based on pulse morphology”. Claim 20 recites the limitation “the arrhythmia” in the limitation “classifying, in real time or near real time, a-the pulse segment of secondary data obtained during the arrhythmia based on pulse morphology”. There is insufficient antecedent basis for this limitation in either claim. For this examination, the “the arrhythmia” is interpreted as referring to some type of previously detected arrhythmia. Regardless if this is applicant’s intention or not, the claims should be amended to give proper antecedent support for arrhythmia. Claims 18-19 are also rejected under 35 USC 112(b) based on dependency to at least one of claims 17 or 20. Allowable Subject Matter Claims 1-20 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.SC. 112(a) or 35 U.S.C. (pre-AIA ), 1st paragraph 35 and/or U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. Please note indication of allowable subject matter is dependent on the interpretation taken and outlined under the 35 USC 112 section above. The following is a statement of reasons for the indication of allowable subject matter: Claim 1 is the broadest independent claim. Claim 1 recites a system for monitoring cardiac arrhythmias. The closest prior art is Kaski. Kaski discloses the invention substantially as claimed as outlined in the previous non-final rejection mailed on 3/5/2025 (see outline under pertinent prior art in that office action). However, Kaski fails to disclose the processor and memory as specifically assigning “a segment value to the pulse segment based on the classification”. Also Kaski fails to disclose the processor and memory as performing the steps of “calculate a shortage value based on a cumulative function in which a previous shortage value is added to the segment value”, “update the shortage value in response to detecting a second heartbeat in the ECG data” and “generate an arrhythmia severity indicator based on the shortage value in which a severity of the indicator tracks a change in the shortage value as the shortage value is updated.” as claimed. Furthermore, nothing in the prior art when viewed with Kaski obviates these deficiencies. It is important to note, that no one single limitation renders the invention allowable. Rather, it is the combination of all the limitations together that defines the invention over the prior art. Therefore, the combination of claimed limitations recited by claim 1 is neither anticipated, nor obviated in view of the prior art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEBASTIAN X LUKJAN whose telephone number is (571)270-7305. The examiner can normally be reached Monday - Friday 9:30AM-6PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, NIKETA PATEL can be reached at 571-272-4156. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SEBASTIAN X LUKJAN /SXL/Examiner, Art Unit 3792 /NIKETA PATEL/Supervisory Patent Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

May 18, 2022
Application Filed
Feb 23, 2025
Non-Final Rejection — §112
Jul 08, 2025
Interview Requested
Jul 23, 2025
Examiner Interview Summary
Jul 23, 2025
Applicant Interview (Telephonic)
Aug 05, 2025
Response Filed
Oct 22, 2025
Final Rejection — §112
Feb 06, 2026
Request for Continued Examination
Feb 28, 2026
Response after Non-Final Action
Mar 03, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599780
LASER THERAPY DEVICE FOR THERAPY OF A LIVING TISSUE
2y 5m to grant Granted Apr 14, 2026
Patent 12569141
SYSTEMS AND METHODS FOR LASER CATHETER TREATMENT IN A VESSEL LUMEN
2y 5m to grant Granted Mar 10, 2026
Patent 12558562
BATTERY POWERED SYSTEMS FOR LIGHT THERAPY AND RELATED METHODS
2y 5m to grant Granted Feb 24, 2026
Patent 12533505
NEUROMODULATION APPARATUS
2y 5m to grant Granted Jan 27, 2026
Patent 12514628
Dermal and Transdermal Cryogenic Microprobe Systems
2y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+41.8%)
3y 2m
Median Time to Grant
High
PTA Risk
Based on 503 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month